MERGE
30.4.2024 10:01:35 CEST | Business Wire | Press release
Merge, which provides unified APIs for B2B SaaS organizations to easily add hundreds of integrations to their products, has officially expanded to Europe with the establishment of its Berlin-based team. The expansion reinforces Merge’s commitment to serving European customers’ integration wants and needs effectively.
Data protection has been a top priority for European organizations since The General Data Protection Regulation (GDPR) took effect in 2018. As a result, Merge remains steadfast in prioritizing investments in security, product infrastructure, and support to assist European companies with their product integration needs.
To ensure the highest standards of security and compliance, Merge maintains ISO 27001 and SOC 2 Type 2 certifications. Additionally, Merge puts in place Data Processing Agreements (DPAs) with all customers, committing to processing data transfers in accordance with GDPR’s Standard Contractual Clauses. Furthermore, Merge supports both multi-tenant and single-tenant environments, enabling customers to fully control where their end-user data is stored.
“We know how important it is for our European customers to securely and quickly offer customer-facing integrations, which is why we’ve prioritized building and enhancing our infrastructure, security-focused features, and Europe-based software integrations,” said Shensi Ding, co-founder and CEO of Merge. “With our new team based in Berlin, we have even faster, dedicated support, providing our customers everything they need to securely and confidently use Merge.”
Merge is proud to be trusted by hundreds of Europe-based companies, including Eloomi, Payhawk, Staffbase, Hofy, TravelPerk, Ledgy, and Causal. Today, 30% of Merge’s customers are based in Europe, and these investments are aimed at better serving this market. Currently offering 200+ global integrations, Merge is focused on adding European providers as it continues to scale.
"Ledgy is being used by organizations in 45+ countries, and Merge has helped us along the way,” said Armon Bättig, head of sales at Zürich-based Ledgy - an equity management platform that uses Merge to power its HRIS integrations.
To learn more about Merge’s integrations for GDPR-compliant companies, visit: www.merge.dev/eu
European companies can visit the Merge booth at Pendomonium’s Mind the Product in London on June 20th, Berlin on June 27th, and at SaaStock in Dublin on October 14th.
About Merge:
Merge is a product integration platform that offers a suite of unified APIs to empower B2B SaaS organizations to seamlessly add hundreds of integrations to their apps. Merge’s platform makes secure data access easy by offering unified APIs across key software categories, including HRIS, accounting, CRM, file storage, and more. By handling the full integration lifecycle, Merge empowers companies to close deals faster, reduce customer churn, and save engineering costs.
Merge is backed by Accel Partners, New Enterprise Associates (NEA), and Addition, and has received $75 million in funding. Merge was founded in 2020 by Shensi Ding and Gil Feig and has offices in San Francisco, New York City and Berlin. For more information, visit Merge's website and follow the company on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430162409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
